Hospira, Inc. has completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., for approximately $400 million.

“We are excited to acquire new capabilities that will create opportunities for commercial growth, position us strongly in a key antibiotics product area, expand our global footprint and enhance our ability to provide lower-cost, high-quality products to patients,” said Terry Kearney, chief operating officer, Hospira. “We’re also excited to welcome a talented base of 450 employees, including newly appointed managing director, Hospira India, Dr. C.B. Rao, who joins us with a wealth of diversified industrial and management experience, and will provide continuity of leadership for the Orchid team joining Hospira.”

“Integration of Orchid’s injectables formulations business with Hospira, the global leader in generic injectables, represents a strong strategic fit. Our team is committed to leveraging our world-class infrastructure, high-technology product range and organizational competencies to drive even greater business growth and strengthen Hospira’s leadership position,” said Dr. Rao.

The acquisition includes Orchid’s beta-lactam antibiotic formulations manufacturing complex and pharmaceutical R&D facility in Chennai, India, as well as its generic injectable dosage-form product portfolio and pipeline. In addition, the companies have signed a long-term agreement for Orchid to supply APIs for the acquired generic injectable pharmaceuticals business.


Click here to learn more about Hospira